AEZS-108: Phase II data

Data from 41 evaluable LHRH-positive ovarian cancer patients in the second stage of the open-label, European Phase II AGO-GYN-5 trial showed that AEZS-108 met the primary endpoint of >=5 patients with partial or complete tumor responses. Patients received six 3-week cycles of 267 mg/m 2 IV AEZS-108. The company previously reported that the first stage of the trial met its target of achieving 2 partial responses in 21 evaluable patients (see BioCentury, Oct. 6, 2008). ...